Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.54 |
| ▸ | CDK1 | P06493 | 7/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | PRKACG | P22612 | 1/20 | 0.40 |
| ▸ | PRKACB | P22694 | 1/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22381492 | 0.89 | CDK1 (0.42) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL27374373 | 0.85 | ADORA2A (0.52) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL18458052 | 0.85 | ADORA2A (0.52) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL27375754 | 0.85 | CDK1 (0.39) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL27375698 | 0.84 | ADORA2A (0.39) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL27374918 | 0.84 | CDK1 (0.40) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL18510386 | 0.83 | CDK2 (0.47) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL27374408 | 0.81 | HPRT1 (0.40) | CDK2CDK1CCNE1CCNB1ADORA2A | |
| SCHEMBL2385929 | 0.81 | HPRT1 (0.55) | CDK2CDK1CCNE1CCNB1MEN1 | |
| SCHEMBL27374338 | 0.79 | HPRT1 (0.39) | CDK2CDK1CCNE1CCNB1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015941-A2 | DINUCLEOTIDES AND THEIR USE IN TREATING CANCER | MAIA BIOTECHNOLOGY, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-06-09 | — | — | US | disclosed |
| WO-2020205323-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2020-04-16 | — | — | US | disclosed |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2019-10-31 | — | — | US | disclosed |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | IDENIX PHARMACEUTICALS LLC (US) | 2018-07-24 | — | — | US | disclosed |
| WO-2018118664-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018118665-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2017-02-02 | — | — | US | disclosed |
| WO-2015081133-A2 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029456-A1 | NUCLEOTIDES FOR THE TREATMENT OF LIVER CANCER | RNMT, NUDT1, NTPCR | CDK2 1588/4885CDK1 931/4885CCNE1 655/4885 |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | CDK2 3890/4885CDK1 1642/4885CCNE1 2421/4885 |
| US-20190328762-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | CDK2 2984/4885CDK1 2009/4885CCNE1 3905/4885 |
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | CDK2 3890/4885CDK1 1642/4885CCNE1 2421/4885 |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | CDK2 3673/4885CDK1 1595/4885CCNE1 2355/4885 |
| US-20220175811-A1 | STABLE FORMULATIONS OF CYCLIC DINUCLEOTIDE STING AGONIST COMPOUNDS AND METHODS OF USE THEREOF | STING1, CGAS, IRF3 | CDK2 4537/4885CDK1 4386/4885CCNE1 4767/4885 |
| US-10030044-B2 | Nucleotides for the treatment of liver cancer | RNMT, NUDT1, NTPCR | CDK2 1588/4885CDK1 931/4885CCNE1 655/4885 |
| US-20200113924-A1 | CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | STING1, CGAS, MAVS | CDK2 2378/4885CDK1 1503/4885CCNE1 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.